News

As per the terms of the agreement, TaiMed is responsible to pay a sum of $250,000 as an upfront payment and might pay up to $7.6m to Ambrilia

Cortex is a neuroscience company engaged in novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea. The company has posted loss from operations of $986,000,

The facility is already certified by the Sustainable Forestry Initiative (SFI), and the dual third-party validations of MWV’s sustainable fiber sourcing practices help assure customers and consumers of

Medidata Solutions is a provider of SaaS-based clinical development solutions that enhance the efficiency of customers’ clinical trials. ViroPharma has choosen Rave as an enterprise-wide EDC system based

XL-protein took over worldwide rights for PASylation technology under a license agreement signed with TUM via Bayerische Patentallianz in 2009. The new patent covers covers the use of

GenSpera owns and controls all rights to Ac-GKAFRR-L12ADT and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials. GenSpera

ZeaVision claims that EyePromise Restore includes the highest available level of Zeaxanthin, the predominant carotenoid found in the fovea, responsible for central vision. ZeaVision president Chris Barber said

As part of the research agreement, bluebird bio has the option to draw upon an additional amount of up to $2.8m in credit toward the manufacturing of cGMP

As per the agreement, Pharmaron is expected to provide Isis Pharma with certain nucleoside phosphoramidites during the next two years. Isis Pharma Medicinal Chemistry Eric Swayze said they